170 related articles for article (PubMed ID: 32994701)
1. Role of Locoregional Treatment in De Novo Stage IV Breast Cancer.
Lee JS; Toktas O; Soran A
Clin Med Insights Oncol; 2020; 14():1179554920942440. PubMed ID: 32994701
[TBL] [Abstract][Full Text] [Related]
2. A prognostic scoring model for survival after locoregional therapy in de novo stage IV breast cancer.
Kommalapati A; Tella SH; Goyal G; Ganti AK; Krishnamurthy J; Tandra PK
Breast Cancer Res Treat; 2018 Aug; 170(3):677-685. PubMed ID: 29721715
[TBL] [Abstract][Full Text] [Related]
3. The role of loco-regional treatment in long-term quality of life in de novo stage IV breast cancer patients: protocol MF07-01Q.
Soran A; Soyder A; Ozbas S; Ozmen V; Karanlik H; Igci A; Muslumanoglu M; Evrensel T; Canturk Z; Utkan Z; Ozaslan C; Uras C; Ugurlu U; Col C; Cabioglu N; Uzunkoy A; Gulluoglu BM; Erdem E; Konca C; Sezgin E;
Support Care Cancer; 2021 Jul; 29(7):3823-3830. PubMed ID: 33242163
[TBL] [Abstract][Full Text] [Related]
4. The Effect of Primary Surgery in Patients with De Novo Stage IV Breast Cancer with Bone Metastasis Only (Protocol BOMET MF 14-01): A Multi-Center, Prospective Registry Study.
Soran A; Dogan L; Isik A; Ozbas S; Trabulus DC; Demirci U; Karanlik H; Soyder A; Dag A; Bilici A; Dogan M; Koksal H; Sendur MAN; Gulcelik MA; Maralcan G; Cabioglu N; Yeniay L; Utkan Z; Simsek T; Karadurmus N; Daglar G; Yildiz B; Uras C; Tukenmez M; Yildirim A; Kutun S; Ozaslan C; Karaman N; Akcay MN; Toktas O; Sezgin E
Ann Surg Oncol; 2021 Sep; 28(9):5048-5057. PubMed ID: 33532878
[TBL] [Abstract][Full Text] [Related]
5. Radiation therapy for primary tumor of
Yoshimura M
Transl Cancer Res; 2020 Aug; 9(8):5108-5116. PubMed ID: 35117877
[TBL] [Abstract][Full Text] [Related]
6. Locoregional Treatment of the Primary Tumor in Patients With De Novo Stage IV Breast Cancer: A Radiation Oncologist's Perspective.
Choi SH; Kim JW; Choi J; Sohn J; Kim SI; Park S; Park HS; Jeong J; Suh CO; Keum KC; Kim YB; Lee IJ
Clin Breast Cancer; 2018 Apr; 18(2):e167-e178. PubMed ID: 28689012
[TBL] [Abstract][Full Text] [Related]
7. Metastatic pattern discriminates survival benefit of primary surgery for de novo stage IV breast cancer: A real-world observational study.
Wang K; Shi Y; Li ZY; Xiao YL; Li J; Zhang X; Li HY
Eur J Surg Oncol; 2019 Aug; 45(8):1364-1372. PubMed ID: 30837102
[TBL] [Abstract][Full Text] [Related]
8. Locoregional therapy of the primary tumour in de novo stage IV breast cancer in 216 066 patients: A meta-analysis.
Gera R; Chehade HELH; Wazir U; Tayeh S; Kasem A; Mokbel K
Sci Rep; 2020 Feb; 10(1):2952. PubMed ID: 32076063
[TBL] [Abstract][Full Text] [Related]
9. Locoregional treatment of
Merloni F; Palleschi M; Gianni C; Casadei C; Curcio A; Romeo A; Rocchi M; Cima S; Sirico M; Sarti S; Cecconetto L; Mariotti M; Di Menna G; De Giorgi U
Front Oncol; 2023; 13():1083297. PubMed ID: 36793604
[TBL] [Abstract][Full Text] [Related]
10. Locoregional therapy in de novo metastatic breast cancer: Systemic review and meta-analysis.
Reinhorn D; Mutai R; Yerushalmi R; Moore A; Amir E; Goldvaser H
Breast; 2021 Aug; 58():173-181. PubMed ID: 34158167
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of Curative-Intent Treatment for Patients With Breast Cancer Presenting With Sternal or Mediastinal Involvement.
Christopherson K; Lei X; Barcenas C; Buchholz TA; Garg N; Hoffman KE; Kuerer HM; Mittendorf E; Perkins G; Shaitelman SF; Smith GL; Stauder M; Strom EA; Tereffe W; Woodward WA; Smith BD
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(3):574-581. PubMed ID: 30851348
[TBL] [Abstract][Full Text] [Related]
12. Metastatic Pattern Discriminates Survival Benefit of Type of Surgery in Patients With
Li K; Zhou C; Yu Y; Niu L; Zhang W; Wang B; He J; Ge G
Front Surg; 2021; 8():696628. PubMed ID: 34805256
[No Abstract] [Full Text] [Related]
13. Primary Surgery with Systemic Therapy in Patients with de Novo Stage IV Breast Cancer: 10-year Follow-up; Protocol MF07-01 Randomized Clinical Trial.
Soran A; Ozmen V; Ozbas S; Karanlik H; Muslumanoglu M; Igci A; Canturk NZ; Utkan Z; Evrensel T; Sezgin E;
J Am Coll Surg; 2021 Dec; 233(6):742-751.e5. PubMed ID: 34530124
[TBL] [Abstract][Full Text] [Related]
14. Randomized Trial Comparing Resection of Primary Tumor with No Surgery in Stage IV Breast Cancer at Presentation: Protocol MF07-01.
Soran A; Ozmen V; Ozbas S; Karanlik H; Muslumanoglu M; Igci A; Canturk Z; Utkan Z; Ozaslan C; Evrensel T; Uras C; Aksaz E; Soyder A; Ugurlu U; Col C; Cabioglu N; Bozkurt B; Uzunkoy A; Koksal N; Gulluoglu BM; Unal B; Atalay C; Yıldırım E; Erdem E; Salimoglu S; Sezer A; Koyuncu A; Gurleyik G; Alagol H; Ulufi N; Berberoglu U; Dulger M; Cengiz O; Sezgin E; Johnson R
Ann Surg Oncol; 2018 Oct; 25(11):3141-3149. PubMed ID: 29777404
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy.
Rossi V; Nolè F; Redana S; Adamoli L; Martinello R; Aurilio G; Verri E; Sapino A; Viale G; Aglietta M; Montemurro F
Breast; 2014 Feb; 23(1):44-9. PubMed ID: 24210572
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes and metastatic behavior between de novo versus recurrent HER2-positive metastatic breast cancer: A 17-year single-institution cohort study at Taipei Veterans General Hospital.
Cheng HF; Tsai YF; Huang CC; Lien PJ; Wang YL; Hsu CY; Chen YJ; Liu CY; Chao TC; Lin YS; Feng CJ; Chiu JH; Chau GY; Tseng LM
J Chin Med Assoc; 2022 Jan; 85(1):88-94. PubMed ID: 34561409
[TBL] [Abstract][Full Text] [Related]
17. The prognostic value of neutrophil-to-lymphocyte ratio in
Shao B; Li H; Liu X; Song G; Jiang H; Yan Y; Zhang R; Ran R; Zhang J; Liu Y; Wang H; Wang J; Di L
Ann Transl Med; 2023 Jan; 11(2):45. PubMed ID: 36819544
[TBL] [Abstract][Full Text] [Related]
18. Can locoregional treatment of the primary tumor improve outcomes for women with stage IV breast cancer at diagnosis?
Nguyen DH; Truong PT; Alexander C; Walter CV; Hayashi E; Christie J; Lesperance M
Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):39-45. PubMed ID: 22330986
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2-Targeted Therapy.
Wong Y; Raghavendra AS; Hatzis C; Irizarry JP; Vega T; Horowitz N; Barcenas CH; Chavez-MacGregor M; Valero V; Tripathy D; Pusztai L; Murthy RK
Oncologist; 2019 Mar; 24(3):313-318. PubMed ID: 30139836
[TBL] [Abstract][Full Text] [Related]
20. Should We Completely Exclude Locoregional Therapy for the Primary Tumor from Our Clinical Practice in De Novo Metastatic Breast Cancer?
Kus T; Aktas G
Ann Surg Oncol; 2022 Sep; 29(9):5359-5360. PubMed ID: 35661954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
